Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.

The present paper investigates the long-term functionality of an ex vivo gene therapy approach based on cell microencapsulation for the continuous delivery of erythropoietin (EPO) without implementation of immunosuppressive protocols. Polymer microcapsules (0.5 ml) loaded with EPO-secreting C(2)C(12) myoblasts and releasing 15,490 +/- 600 IU EPO/24 h were implanted in the peritoneum and subcutaneous tissue of syngeneic and allogeneic mice. High and constant hematocrit levels were maintained for more than 100 days in all implanted mice. Capsules retrieved from the peritoneum were free-floating or forming small capsule clusters, and we detected only a weak fibroblast outgrowth in capsules adhered to organs, whereas capsules explanted from the subcutaneous region appeared altogether as a richly vascularized structure with no signs of major host reaction. Interestingly, the functionality of capsules implanted in the allogeneic mice persisted until day 210 after implantation. These results highlight the feasibility of cell encapsulation technology for the long-term delivery of EPO independent of the method of administration and the mouse strain.

[1]  Anthony Atala,et al.  Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.

[2]  G. Reach,et al.  In vitro kinetics of insulin release by microencapsulated rat islets: effect of the size of the microcapsules , 1988, Diabetologia.

[3]  J. Hallé,et al.  Effect of poly-L-lysine coating on macrophage activation by alginate-based microcapsules: assessment using a new in vitro method. , 2005, Journal of biomedical materials research. Part A.

[4]  R. van Schilfgaarde,et al.  Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. , 2003, The Journal of surgical research.

[5]  K Arnold,et al.  A highly sensitive cell assay for validation of purification regimes of alginates. , 2003, Biomaterials.

[6]  L. Kunz,et al.  The role of oxygen supply in islet transplantation. , 1992, Transplantation proceedings.

[7]  J. Pedraz,et al.  Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. , 2002, Biomaterials.

[8]  K. Maiese,et al.  Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8 , 2003, Journal of neuroscience research.

[9]  D. Ribatti,et al.  Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo , 1999 .

[10]  J. Pedraz,et al.  Survival of different cell lines in alginate-agarose microcapsules. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  A. Sun,et al.  Xenografts of rat islets into diabetic mice. An evaluation of new smaller capsules. , 1992, Transplantation.

[12]  T. Chang,et al.  Secretion of Erythropoietin from Microencapsulated Rat Kidney Cells: Preliminary Results , 1993, The International journal of artificial organs.

[13]  I. Macdougall,et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[14]  N. Olsen.  Central nervous system frontiers for the use of erythropoietin. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Y. Kato,et al.  Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. , 1998, European journal of endocrinology.

[16]  D. Bohl,et al.  Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. , 1997, Human gene therapy.

[17]  A. Anilkumar,et al.  An encapsulation system for the immunoisolation of pancreatic islets , 1997, Nature Biotechnology.

[18]  P. de Vos,et al.  Considerations for successful transplantation of encapsulated pancreatic islets , 2002, Diabetologia.

[19]  N. Déglon,et al.  Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  R. Robitaille,et al.  Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers. , 2005, Biomaterials.

[21]  W. Jelkmann.  Erythropoietin: structure, control of production, and function. , 1992, Physiological reviews.

[22]  T. Clackson,et al.  Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Alan Dove,et al.  Cell-based therapies go live , 2002, Nature Biotechnology.

[24]  T. Chang,et al.  Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats , 1996, Nature Medicine.

[25]  N. Déglon,et al.  Optimization of human erythropoietin secretion from MLV‐infected human primary fibroblasts used for encapsulated cell therapy , 2003, The journal of gene medicine.

[26]  F. Lim,et al.  Microencapsulated islets as bioartificial endocrine pancreas. , 1980, Science.

[27]  K. Maiese,et al.  Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase‐mediated pathways , 2003, British journal of pharmacology.

[28]  F. Thürmer,et al.  Biocompatible alginate from freshly collected Laminaria pallida for implantation , 2000, Applied Microbiology and Biotechnology.

[29]  P. Vos,et al.  Cell encapsulation: Promise and progress , 2003, Nature Medicine.

[30]  J. Pedraz,et al.  Biocompatibility evaluation of different alginates and alginate-based microcapsules. , 2005, Biomacromolecules.

[31]  P Aebischer,et al.  Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts , 1998, Gene Therapy.

[32]  N. Déglon,et al.  Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts , 1999, Gene Therapy.

[33]  R. Robitaille,et al.  Studies on small (<350 microm) alginate-poly-L-lysine microcapsules. III. Biocompatibility Of smaller versus standard microcapsules. , 1999, Journal of biomedical materials research.

[34]  P. Aebischer,et al.  Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  T. Chang,et al.  Therapeutic applications of polymeric artificial cells , 2005, Nature Reviews Drug Discovery.

[36]  G. Klöck,et al.  Production of purified alginates suitable for use in immunoisolated transplantation , 2004, Applied Microbiology and Biotechnology.

[37]  P. Tresco,et al.  Technology of mammalian cell encapsulation. , 2000, Advanced drug delivery reviews.

[38]  D. Martineau,et al.  Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modified marrow stromal cells. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.